ArticleInvestigational new drugs2020

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.

Johanna C Bendell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.